Paclitaxel Injection, Solution
Product Images NDC 63323-763

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Paclitaxel (NDC 63323-763). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton 100mg

Paclitaxel Injection, USP 6 mg per mL (100 mg per 16.7 mL vial) label from Fresenius Kabi USA, LLC. The label includes storage instructions for 20° to 25°C, a warning as a cytotoxic agent, and instructions that the product must be diluted prior to intravenous use. It is a sterile, nonpyrogenic multiple-dose vial. The label also features the NDC 63323-763-16 and company contact information.*

FDA Label Image

Carton 300mg

Packaging label for Paclitaxel Injection, USP (semisynthetic) by Fresenius Kabi USA, LLC, with a strength of 6 mg per mL offered as 300 mg per 50 mL multiple dose vial. The label includes storage instructions, warnings about cytotoxicity, and emphasizes dilution prior to intravenous use. The label also features product barcodes and contact information for the manufacturer.*

FDA Label Image

Carton30mg

Packaging label for Paclitaxel Injection, USP (semisynthetic), 6 mg/mL concentration, with a total of 30 mg per 5 mL vial. Labeled as a cytotoxic agent, it includes storage instructions at 20° to 25°C, and warnings to protect from light and dilute prior to intravenous use. Labeler is Fresenius Kabi USA, LLC, with contact information and barcode visible.*

FDA Label Image

Fig-1 (Fig 1)

A survival curve graph depicting the proportion of patients surviving over a period of 0 to 5 years. The graph compares two groups labeled Cc and Tc, showing a higher survival proportion over time for Cc. A data inset presents patient numbers, events, and a hazard ratio with 95% confidence interval comparing the groups.*

FDA Label Image

Fig2 (Fig2)

A survival curve graph titled "Figure 2. Survival: Cc Versus Tc (GOG-111)" showing proportion surviving on the vertical axis and years on the horizontal axis from 0 to 5 years. It compares two groups, Cc and Tc, with Cc group having higher survival proportion over time. A table inset displays sample sizes (N), number of events, and hazard ratio (HR) with 95% confidence interval for each group.*

FDA Label Image

Logo (Logo)

FDA Label Image

Paclitaxel-fig3 (Paclitaxel Fig3)

A line graph titled "Disease-Free Survival: AC Versus AC+T" showing proportion disease-free over 4 years. It compares two treatment groups, AC and AC+T, with AC+T showing a higher proportion disease-free. The graph includes a table with number of subjects, events, and hazard ratio (HR 0.78) with confidence interval (0.67-0.91), and a "Number at Risk" row for both groups at specified years.*

FDA Label Image

Paclitaxel-fig4 (Paclitaxel Fig4)

A survival curve chart titled 'Figure 4. Survival: AC Versus AC+T' comparing the proportion surviving over a 4-year period between two groups labeled AC and AC+T. The chart includes a risk table with numbers at risk at different time points, hazard ratio (HR) 0.74 with 95% confidence interval (0.6-0.92), and number of events for each group.*

FDA Label Image

Paclitaxel-fig5 (Paclitaxel Fig5)

A survival curve chart titled 'Disease-Free Survival - Receptor Status Negative/Unknown AC Versus AC+T,' displaying proportion disease-free over 4 years. Two curves represent AC and AC+T groups, with AC+T showing higher proportion disease-free. The chart includes a table of number of events, hazard ratio (HR), and confidence interval (CI), plus numbers at risk by year for each group.*

FDA Label Image

Paclitaxel-fig6 (Paclitaxel Fig6)

A survival curve chart titled 'Disease-Free Survival - Receptor Status Positive AC Versus AC+T' showing the proportion of disease-free patients over a period of 4 years. The chart compares two groups, AC and AC+T, with lines representing their survival proportions. A table within the graph provides the number of patients, events, hazard ratio, and confidence interval for each group, along with the number at risk at various time points.*

FDA Label Image

Paclitaxel-fig7 (Paclitaxel Fig7)

A Kaplan-Meier curve graph showing disease-free survival over 4 years for premenopausal patients comparing AC versus AC+T treatments. The y-axis represents the proportion of patients disease-free, and the x-axis shows years. The chart includes a legend and data for number at risk and events for both treatment groups.*

FDA Label Image

Paclitaxel-fig8 (Paclitaxel Fig8)

A line chart titled 'Disease-Free Survival - Postmenopausal AC Versus AC+T' comparing the proportion of disease-free patients over four years between two groups: AC (dotted line) and AC+T (solid line). The chart includes a table with number of patients (N), events, hazard ratio (HR), and 95% confidence interval (CI), displaying better disease-free survival for the AC+T group.*

FDA Label Image

Paclitaxel (Paclitaxel)

Chemical structure diagram of the active ingredient Paclitaxel, showing its molecular framework with rings, functional groups, and stereochemistry typical of the molecule.*

FDA Label Image

Vial 100mg

Paclitaxel Injection, USP (6 mg/mL) label for a multiple dose vial. The label states 100 mg per 16.7 mL concentration, with instructions that the product must be diluted prior to intravenous use and notes it as a cytotoxic agent. The label shows the Fresenius Kabi USA, LLC as the manufacturer and includes storage instructions and other regulatory information.*

FDA Label Image

Vial 300mg

Paclitaxel Injection, USP 300 mg per 50 mL (6 mg/mL) label showing a sterile, nonpyrogenic multiple dose vial for intravenous use. The label includes storage instructions (20° to 25°C), dilution warning, and manufacturer Fresenius Kabi USA, LLC. It features the product NDC 63323-763-50 and barcode.*

FDA Label Image

Vial 30mg

Label for Paclitaxel Injection USP, 30 mg per 5 mL (6 mg/mL) multiple dose vial from Fresenius Kabi USA, LLC. The label includes dilution requirement for intravenous use, storage instructions, and manufacturer location in Lake Zurich, IL. It features a barcode and NDC 63323-763-05.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.